Log In
Print
BCIQ
Print
Print this Print this
 

Onglyza, saxagliptin (BMS-477118, OPC-262)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionOral dipeptidyl peptidase-4 (DPP-4; CD26) inhibitor
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26)
Mechanism of ActionDipeptidyl peptidase-4 (DPP-4) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat adults with Type II diabetes who have moderate or severe renal impairment; Treat Type II diabetes
Regulatory Designation
Partner Kyowa Hakko Kirin Co. Ltd.; Otsuka Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$4,240.0M

$2,737.5M

$1,502.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today